<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227603</url>
  </required_header>
  <id_info>
    <org_study_id>14027</org_study_id>
    <secondary_id>2010-021966-31</secondary_id>
    <nct_id>NCT01227603</nct_id>
  </id_info>
  <brief_title>Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions</brief_title>
  <official_title>Single Dose Study to Compare the Pharmacokinetics as Well as Safety and Tolerability of a Novel Fixed Dose Combination of Nifedipine GITS and Candesartan, the Loose Combination of Both and the Single Components Alone and to Investigate the Bioequivalence Between the Fixed Dose and the Loose Combination in Healthy Male Volunteers Under Fasting Conditions in an Open Label, Randomized, 4-way-crossover Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, open label, single dose, 4-way crossover study to investigate the bioequivalence
      of a new fixed dose combination tablet of nifedipine GITS and candesartan with the
      corresponding loose combination and to compare it with the individual drugs
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Within 48 hours after each treatment</time_frame>
    <description>Maximum drug concentration in plasma after dose administration for nifedipine and candesartan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tn)</measure>
    <time_frame>Within 48 hours after each treatment</time_frame>
    <description>AUC from time 0 to the last data point for nifedipine and candesartan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Within 48 hours after each treatment</time_frame>
    <description>Area under the plasma concentration vs time curve from zero to infinity after single (first) dose for nifedipine and candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,norm</measure>
    <time_frame>Within 48 hours after each treatment</time_frame>
    <description>Maximum drug concentration in plasma after dose administration divided by dose (mg) per kg body weight for nifedipine and candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCnorm</measure>
    <time_frame>Within 48 hours after each treatment</time_frame>
    <description>Area under the curve divided by dose per kg body weight for nifedipine and candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-48)</measure>
    <time_frame>Within 48 hours after each treatment</time_frame>
    <description>AUC from time 0 to time 48 h for nifedipine and candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>Within 48 hours after each treatment</time_frame>
    <description>Time to reach maximum drug concentration in plasma after single (first) dose for nifedipine and candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½</measure>
    <time_frame>Within 48 hours after each treatment</time_frame>
    <description>Half-life associated with the terminal slope for nifedipine and candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT</measure>
    <time_frame>Within 48 hours after each treatment</time_frame>
    <description>Mean residence time for nifedipine and candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/f</measure>
    <time_frame>Within 48 hours after each treatment</time_frame>
    <description>Total body clearance of drug from plasma calculated after oral administration (apparent oral clearance) for nifedipine and candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Approximately 3.5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Hypertension, Essential</condition>
  <arm_group>
    <arm_group_label>Nifedipine-candesartan FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject received single fixed dose combination of 60 mg nifedipine and 32 mg candesartan orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine and candesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject received one dose of nifedipine GITS 60 mg and candesartan 32 mg (2 x 16 mg tablet) as loose combination, orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject received one dose of nifedipine GITS 60 mg orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Candesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject received one dose of candesartan 32 mg (2 x 16 mg tablet), orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine-candesartan FDC (BAY 98-7106)</intervention_name>
    <description>Single dose of 1 FDC tablet consisting of 60 mg nifedipine GITS and 32 mg candesartan</description>
    <arm_group_label>Nifedipine-candesartan FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine GITS (Adalat LA, BAYA1040)</intervention_name>
    <description>Single oral dose of 1 tablet of nifedipine GITS 60 mg</description>
    <arm_group_label>Nifedipine and candesartan</arm_group_label>
    <arm_group_label>Nifedipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan (Atacand)</intervention_name>
    <description>Single oral dose of 32 mg (2 x 16 mg tablet) candesartan</description>
    <arm_group_label>Nifedipine and candesartan</arm_group_label>
    <arm_group_label>Candesartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subject

          -  Age: 18 to 45 years (inclusive) at the first screening / examination visit

          -  Ethnicity: Caucasian

          -  Body mass index (BMI): &gt;/=18 and &lt;/=29,9 kg/m²

        Exclusion Criteria:

          -  Systolic blood pressure below 120 or above 145 mmHg

          -  Diastolic blood pressure above 95 mmHg

          -  Heart rate below 45 or above 95 beats / min

          -  Clinically relevant findings in the physical examination

          -  Suspicion of drug or alcohol abuse

          -  Regular daily consumption of more than 1 L of xanthin-containing beverages

          -  Intake of foods or beverages containing grapefruit within 4 weeks before the pre-study
             examination
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <results_reference>
    <citation>Brendel E, Weimann B, Dietrich H, Froede C, Thomas D. Investigation of bioequivalence of a new fixed-dose combination of nifedipine and candesartan with the corresponding loose combination as well as the drug-drug interaction potential between both drugs under fasting conditions. Int J Clin Pharmacol Ther. 2013 Sep;51(9):753-62. doi: 10.5414/CP201879.</citation>
    <PMID>23849325</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2010</study_first_submitted>
  <study_first_submitted_qc>October 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2010</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Nifedipine</keyword>
  <keyword>Candesartan</keyword>
  <keyword>FDC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

